18 December 2013

Regeneron to establish biopharmaceutical production facility in Limerick, Ireland

Limerick - 18 December 2013 - Regeneron Pharmaceuticals, Inc. is to apply for planning permission to establish a biopharmaceutical production facility within a 11.88 hectare site, previously owned by Dell in the Raheen Business Park, Limerick, Ireland. This project is supported by the Department of Jobs through IDA Ireland, which has worked with the company for the past four years to attract it to invest in Ireland. 

Subject to planning approval from the local authority, the company expects to employ up to 300 people by the end of 2016. The proposed $300 million investment programme will involve the major refurbishment of existing buildings on the site (vacant since 2009) and the construction of a quality control laboratory. Subject to a successful permit, construction and refurbishment is anticipated to begin in 2014 for a two-year period, generating up to 600 temporary construction jobs for local contractors.

“Regeneron is one of the largest and fastest-growing biopharmaceutical companies in the United States," said Daniel Van Plew, Regeneron’s Senior VP & GM of Industrial Operations and Product Supply. "Pending planning approval, Limerick will become our second industrial production site, expanding our manufacturing capacity into Europe and facilitating the delivery of a growing supply of medicines for patients worldwide.”

Welcoming the announcement, the Minister for Jobs, Enterprise and Innovation, Richard Bruton, TD said, “Sustaining and building on Ireland’s strong track record in pharmaceuticals is a key objective of our Action Plan for Jobs. In recent years despite global difficulties employment in the sector in Ireland has been growing. Today’s announcement that subject to planning permission, Regeneron plans to establish a major operation in Limerick with the creation of 300 jobs is another significant jobs boost for the sector and for the city. With Regeneron confirming its intention to establish operations in Ireland, IDA Ireland with the support of my Department has now secured nine of the top ten global BioPharma companies to locate major facilities in Ireland. I am determined to build on this and secure further announcements like this over the coming months.”

Commenting on the announcement, Barry O’Leary, CEO of IDA Ireland said, “Regeneron’s decision to locate this strategically important investment here is a clear endorsement of Ireland’s recognised strengths in the pharma and BioPharma field. BioPharma companies like Regeneron are currently developing and manufacturing the “next generation” of medicines. This activity represents the cutting edge of innovative drug development and requires skilled, highly qualified staff. This announcement is a reflection of the attractiveness of Limerick and the Mid-West region to leading global investors. Regeneron joins a thriving life science sector in the region which offers excellent employment opportunities and makes a substantial contribution to the local economy. IDA Ireland took a strategic decision to target the biopharma sector in recent years.”

Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York, USA, that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis. 

Source: IDA Ireland